Therapeutic drug monitoring of antidepressants - Cost implications and relevance to clinical practice

被引:62
作者
Burke, MJ [1 ]
Preskorn, SH [1 ]
机构
[1] Univ Kansas, Sch Med, Dept Psychiat & Behav Sci, Wichita, KS 67214 USA
关键词
D O I
10.2165/00003088-199937020-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite evidence to support its potential benefit in clinical practice, therapeutic drug monitoring (TDM) is under-utilised and underdeveloped in the field of psychiatry. In antidepressant pharmacotherapy drug dose is emphasised as the critical treatment variable. However, dose in, and of, itself can be a strikingly misleading predictor of drug concentration and, hence, treatment effect. For antidepressant drugs, plasma concentrations at a given dose have been shown to vary in excess of 40-fold. The clinical relevance of this variability is that at a standard antidepressant dosage only some patients will have tissue drug concentrations associated with an optimal response whereas others will have either low, ineffective drug concentrations or unnecessarily high concentrations which may be poorly tolerated. Among clinicians and healthcare agencies there is an under-appreciation of the degree of pharmacokinetic variability found in patients and how that might impact on the patients response to pharmacotherapy. Hence there is a perception that TDM is an unnecessary, complicated and costly procedure. This is actually unfounded. There are data to suggest that TDM can favourably affect the outcome of antidepressant treatment by providing a rational alternative to the inherently slower, trial and error practice of dosage titration based on clinical response. It is unlikely that TDM will become a standard of care for all antidepressant agents and all patients. Therefore the question becomes for which antidepressant agents, for which patients and under what circumstances, is TDM more cost-effective than traditional dose titration. The use of TDM to optimise the efficient use of selected antidepressant agents could potentially free up healthcare resources to fund other equally deserving treatments. This article provides a discussion of the major classes of antidepressant drugs with regard to their pharmacological features that predict the utility of TDM in clinical practice. Recommendations are made for the practical application of TDM and the directions for further research.
引用
收藏
页码:147 / 165
页数:19
相关论文
共 86 条
[1]   THE EVIDENCE FOR 20 MG A DAY OF FLUOXETINE AS THE OPTIMAL DOSE IN THE TREATMENT OF DEPRESSION [J].
ALTAMURA, AC ;
MONTGOMERY, SA ;
WERNICKE, JF .
BRITISH JOURNAL OF PSYCHIATRY, 1988, 153 :109-112
[2]  
Amsterdam JD, 1997, AM J PSYCHIAT, V154, P963
[3]  
BALANTGORGIA AE, 1989, THER DRUG MONIT, V11, P415
[4]   THE PHARMACOKINETICS OF PAROXETINE IN THE ELDERLY [J].
BAYER, AJ ;
ROBERTS, NA ;
ALLEN, EA ;
HORAN, M ;
ROUTLEDGE, PA ;
SWIFT, CG ;
BYRNE, MM ;
CLARKSON, A ;
ZUSSMAN, BD .
ACTA PSYCHIATRICA SCANDINAVICA, 1989, 80 :85-86
[5]  
BEASLEY CM, 1991, J CLIN PSYCHIAT, V52, P294
[6]   RELATIONSHIP BETWEEN CLINICAL EFFECTS, SERUM DRUG CONCENTRATION AND SEROTONIN UPTAKE INHIBITION IN DEPRESSED-PATIENTS TREATED WITH CITALOPRAM - A DOUBLE-BLIND COMPARISON OF 3 DOSE LEVELS [J].
BJERKENSTEDT, L ;
FLYCKT, L ;
OVERO, KF ;
LINGJAERDE, O .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (05) :553-557
[7]   BLOCKADE BY NEWLY-DEVELOPED ANTIDEPRESSANTS OF BIOGENIC-AMINE UPTAKE INTO RAT-BRAIN SYNAPTOSOMES [J].
BOLDENWATSON, C ;
RICHELSON, E .
LIFE SCIENCES, 1993, 52 (12) :1023-1029
[8]  
BURGHART SM, 1998, DRUG UTILIZATION REV, V20, P1
[9]  
BURKE MJ, 1994, J CLIN PSYCHIAT, V55, P42
[10]  
BURKE MJ, 1996, J PRACT PSYCHIAT BEH, V2, P2